Tissue Regeneration Therapeutics (TRT) is a progressive biotechnology company with a focus on the commercial development of our patented Human Umbilical Cord PeriVascular Cell (HUCPVC) platform technology and its TXP family of cell therapy products. TRT has discovered the world's richest source of mesenchymal stromal/stem cells (MSCs) with potent regenerative, angiogenic, anti-inflammatory, and immuno-regulatory properties. Unique advantages of the TRT HUCPVC platform technology are founded on the highly enriched source of these important cells compared to other tissue sources
With our partners we create cellular and regenerative strategies that maximize the utility of our platform technology and products - for therapies that address important health care issues of today.
Together, we build very powerful biology.
June 30, 2020 - Tissue Regeneration Therapeutics
receives Certificate of Patent for Canadian Patent Application No. 2871219 “Immune Privileged and Modulatory Progenitor Cells”.
June 19, 2020 - Tissue Regeneration Therapeutics
receives Notice of Allowance for Canadian Patent Application No. 2721870 “Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents”.
March 18, 2020 - Tissue Regeneration Therapeutics
and Shanghai Zhiquan Biological Technology Co., Ltd.
Sign a Technology Cooperation Agreement regarding the commercialization of human umbilical cord perivascular cell (HUCPVC) derivative-related technology in China.
Click here for more news...